TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02757144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012
Description: DWP14012 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study: NCT03213808

Intervention type: OTHER
Intervention: No intervention: analysis of health data from patients with
Description: No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
Study: NCT01785082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-C-Methacetin
Description: intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
Study: NCT00897715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: 160 mg of rilonacept administered subcutaneously once a week for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 160 mg of placebo administered subcutaneously once a week for 12 weeks
Study: NCT04773366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine+Mercaptopurine
Description: Group 1 Maintenance continuation treatment (W25\~52) . Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w; Cytarabine 100mg/m2 iv/IH d1-4 q6w ×3 times (w25,31,37); 6-MP 50mg/m2/d,po,qn

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+Cytarabine+vincristine
Description: Group 2 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6; Cytarabine 100mg/m2 iv/IH d1-4 q2w (w1,3,5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine+Mercaptopurine
Description: Group 2 continuation treatment (W7\~W52) . Prednisone 40mg/m2 d1-5 q3w; VCR 1.5/m2 iv d1 q3w; 6-MP 50mg/m2/d,po,qn

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine
Description: Group 3 Initial treatment (W1\~W6) . Prednisone 40mg/m2×4w, taper 2w; Vincristine 1.5mg/m2 iv d1 of w1,2,3,4,5,6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone+vincristine
Description: . Group 3 Continuation treatment (W7\~W52)Prednisone 40mg/m2 d1-5 q3w; Vincristine 1.5/m2 iv d1 q3w

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local therapy
Description: Local therapy/wait and see. Group 4
Study: NCT02500134

Intervention type: OTHER
Intervention: Optical coherence tomography study on limbus
Description: Optical coherence tomography study on limbus
Study: NCT00681876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erbitux
Description: Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
Study: NCT03575806

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TACE plus autologous Tcm immunotherapy
Description: TACE:transcatheter arterial chemoembolization.~Autologous Tcm immunotherapy: to collect patient's own immune cells and then given back to the patient after amplified in vitro.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE:transcatheter arterial chemoembolization.
Study: NCT01829659

Intervention type: DRUG
Intervention: Ticagrelor
Study: NCT00768911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-322
Description: Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week~Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week
Study: NCT02563366

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BM-MSCs
Description: BM-MSCs are from third-party healthy volunteer donors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline is the placebo of MSCs in this study.
Study: NCT02926352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction Training
Description: Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Extinction Training
Description: Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: 1064nm light used to modulate a biological function and induce a therapeutic effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: 1064nm light used to modulate a biological function and induce a therapeutic effect.
Study: NCT02757144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: DWP14012 placebo-matching tablets, Active control placebo-matching tablets
Study: NCT02926352

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Low-Level Laser Therapy
Description: Placebo dose version of LLLT.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low-Level Laser Therapy
Description: Placebo dose version of LLLT.
Study: NCT02160223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
Study: NCT02434029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 1mg orodispersible tablet twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo orodispersible tablet twice daily
Study: NCT00777920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Tablet administered orally once daily
Study: NCT03585166

Intervention type: PROCEDURE
Intervention: lpaparoscopic hepatectomy
Description: laparoscopic hepatectomy： laparoscopic hepatectomy for hepatocellular carcinoma.

Intervention type: PROCEDURE
Intervention: open hepatectomy
Description: open hepatectomy: open hepatectomy for hepatocellular carcinoma
Study: NCT01872832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 and Placebo
Study: NCT02860546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: One Arm Only (of TAS 102 plus nivolumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: One Arm Only (of TAS 102 plus nivolumab)
Study: NCT02245516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 0.25% Ophthalmic Suspension
Description: KPI-121 drug product will be supplied a 0.25% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT01872832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 and Placebo
Study: NCT04061837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitralStitch
Description: With transesophageal echocardiographic guidance,implanting ePTFE sutures as artificial chordae or ege-to-ege repair using MitralStitch Mitral Valve Repair System
Study: NCT00666952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Decision Aid
Description: Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
Study: NCT02245516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPI-121 1.0% Ophthalmic Suspension
Description: KPI-121 drug product will be supplied a 1.0% loteprednol etabonate as a suspension packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
Study: NCT02652975

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SphygmoCor
Description: Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.~Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 24hour blood pressure
Description: 24 hour blood pressure measurement
Study: NCT00768911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)~150 mg/M2/day X 5 days; adjuvant cycle #1~200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
Study: NCT00513240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoetin
Description: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.~.
Study: NCT01707290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: 150 mg tablet, oral use, every 12 hours (q12h)
Study: NCT00218712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Description: Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
Study: NCT03458078

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Spinal injection of 10 mg hyperbaric bupivacaine 0.5% (2 ml) + 100γ morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 1 ml physiological saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ sufentanil (0.5ml) + 100 mg MgSO4 (1 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam 5 MG/ML Injection
Description: Spinal injection of 10 mg hyperbaric Bupivacaine 0.5% (2 ml) + 100γ Morphine (1ml) + 2.5 γ Sufentanil (0.5ml) + 2mg Midazolam (0.4 + 0.6cc physiological saline (1 ml)).
Study: NCT00750425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib (RECENTIN TM, AZD2171)
Description: 20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
Study: NCT00944099

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Description: both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
Study: NCT00383253

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 10%
Description: Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 25%
Description: Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction - 50%
Description: Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: caloric restriction - Control
Description: Subjects maintained on their baseline caloric intake (caloric restriction = none)
Study: NCT02242253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: administered via HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: administered via HandiHaler®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: administered via HandiHaler®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: administered via metered dose inhaler (MDI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: administered via metered dose inhaler (MDI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: administered via metered dose inhaler (MDI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo HandiHaler®
Study: NCT02364765

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
Study: NCT01653535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fast Track
Description: First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
Study: NCT04781426

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate (TDF) 300 mg
Description: PrEP regimens of Tenofovir Disoproxil Fumarate (TDF) 300 mg/Lamivudine (3TC) 300mg per oral (PO) daily
Study: NCT01173120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abatacept combination product (ACP)
Description: Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
Study: NCT02002221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin (LAF237)
Description: Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo of vildagliptin 50 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.~The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Patients continued their prescribed metformin dose, if applicable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued their prescribed metformin dose, if applicable.
Study: NCT04413019

Intervention type: OTHER
Intervention: Clinical follow up
Description: Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection.

Intervention type: OTHER
Intervention: Clinical follow up
Description: Patients recruited in this study commenced antibiotic treatment according to the recent guidelines :~* Erythromycin 250 mg 4 times daily for 10 days following the diagnosis of PPROM, or until the women is established labor (whichever sooner)~* Penicillin may be used in patients who can't tolerate erythromycin~* In cases of penicillin allergy: Cefazolin 1 g intravenously every 8 hours for 48 hours, followed by cephalexin 500 mg orally four times daily for five days. These drugs provide coverage for both GBS and Escherichia coli, the two major causes of neonatal infection.
Study: NCT05664360

Intervention type: OTHER
Intervention: Age (young versus older)
Description: Age
Study: NCT03811691

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI exam
Description: Pacing system safety and stability under MRI scan environment

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI exam
Description: Pacing system safety and stability under MRI scan environment
Study: NCT03054233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crossed leg sitting position
Description: Spinal anesthesia done in crossed leg sitting position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crossed leg sitting position
Description: Spinal anesthesia done in crossed leg sitting position
Study: NCT02107131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab 0.3mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal ranibizumab 0.3mg
Study: NCT02757144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Nexium®

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Nexium®